Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)

INTRODUCTION: Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tamura, Yuichi, Ono, Tomohiko, Fukuda, Keiichi, Satoh, Toru, Sasayama, Shigetake
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2013
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3680653/
https://ncbi.nlm.nih.gov/pubmed/23653230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-013-0029-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky